INT222301

From wiki-pain
Revision as of 17:52, 20 September 2012 by Daniel (Talk | contribs)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Context Info
Confidence 0.36
First Reported 2007
Last Reported 2010
Negated 1
Speculated 0
Reported most in Body
Documents 5
Total Number 6
Disease Relevance 5.07
Pain Relevance 0.29

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytoplasm (ERBB2, ESR1) signal transduction (ERBB2, ESR1) nucleus (ERBB2, ESR1)
plasma membrane (ERBB2, ESR1) nucleoplasm (ESR1) enzyme binding (ESR1)
ERBB2 (Homo sapiens)
ESR1 (Homo sapiens)
Pain Link Frequency Relevance Heat
palliative 24 86.36 High High
Inflammation 32 71.76 Quite High
imagery 2 50.04 Quite High
cva 5 5.00 Very Low Very Low Very Low
agonist 4 5.00 Very Low Very Low Very Low
headache 4 5.00 Very Low Very Low Very Low
cytokine 3 5.00 Very Low Very Low Very Low
sSRI 3 5.00 Very Low Very Low Very Low
Pain 3 5.00 Very Low Very Low Very Low
Dismenorea 2 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Cancer 168 100.00 Very High Very High Very High
Breast Cancer 119 99.72 Very High Very High Very High
Metastasis 22 97.72 Very High Very High Very High
Reprotox - General 1 48 92.08 High High
Disease 44 91.92 High High
Rheumatoid Arthritis 52 90.96 High High
Apoptosis 97 89.24 High High
Advanced Or Metastatic Breast Cancer 21 85.20 High High
Targeted Disruption 2 83.88 Quite High
Recurrence 10 83.44 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
-catenin signaling pathway was associated with ER- ERBB2-amplified tumors. ?
ERBB2 Binding (associated) of ER associated with cancer
1) Confidence 0.36 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2958950 Disease Relevance 0.62 Pain Relevance 0.07
Subgroups were classified on the basis of ER, PR, and HER2 IHC findings with 71 of the 110 patients (64.5%) being HR+, 14 patients (12.7%) HER2+, and 25 patients (22.7%) TN.
HER2 Binding (findings) of ER
2) Confidence 0.33 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2972282 Disease Relevance 0.62 Pain Relevance 0.11
Subgroups were classified on the basis of ER, PR, and HER2 IHC findings with 71 of the 110 patients (64.5%) being HR+, 14 patients (12.7%) HER2+, and 25 patients (22.7%) TN.
HER2 Binding (findings) of ER
3) Confidence 0.29 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2972282 Disease Relevance 0.63 Pain Relevance 0.11
As models, we have used ER-positive (BT474) and ER-negative (SKBR3) HER2-overexpressing human breast cancer cell lines.
HER2-overexpressing Binding (used) of ER-negative associated with breast cancer
4) Confidence 0.15 Published 2010 Journal Breast Cancer Res Section Body Doc Link PMC2949655 Disease Relevance 1.28 Pain Relevance 0
As models, we have used ER-positive (BT474) and ER-negative (SKBR3) HER2-overexpressing human breast cancer cell lines.
HER2-overexpressing Binding (used) of ER-positive associated with breast cancer
5) Confidence 0.13 Published 2010 Journal Breast Cancer Res Section Body Doc Link PMC2949655 Disease Relevance 1.28 Pain Relevance 0
Patients who have ER-positive tumours with unfavourable characteristics, such as HER-2 positivity, PgR negativity or nodal positivity, are likely to be selected for immediate AI therapy.
HER-2 Neg (negativity) Binding (negativity) of ER associated with cancer
6) Confidence 0.02 Published 2007 Journal International Journal of Clinical Practice Section Body Doc Link PMC2228389 Disease Relevance 0.66 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox